The estimated Net Worth of Reinhard J. Ambros is at least $16.7 Thousand dollars as of 15 June 2020. Reinhard Ambros owns over 5,800 units of Aileron Therapeutics Inc stock worth over $16,704 and over the last 7 years he sold ALRN stock worth over $0. In addition, he makes $0 as Lead Independent Director at Aileron Therapeutics Inc.
Reinhard has made over 2 trades of the Aileron Therapeutics Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he bought 5,800 units of ALRN stock worth $7,076 on 15 June 2020.
The largest trade he's ever made was buying 266,667 units of Aileron Therapeutics Inc stock on 5 July 2017 worth over $4,000,005. On average, Reinhard trades about 27,247 units every 108 days since 2017. As of 15 June 2020 he still owns at least 5,800 units of Aileron Therapeutics Inc stock.
You can see the complete history of Reinhard Ambros stock trades at the bottom of the page.
Dr. Reinhard J. Ambros Ph.D. serves as Lead Independent Director of the Company. serves as Independent Director of the Company. Dr. Ambros served as global head of Novartis Venture Funds. He previously served as head of group strategic planning for Novartis AG, a multinational pharmaceutical company, from 2001 until 2005, and as global head of business development and licensing for cardiovascular and metabolic diseases at Novartis Pharma AG. He currently serves on the board of several biotechnology companies in Europe and the United States. He also serves as advisor to German and Swiss Government Biotechnology Funds. Dr. Ambros received an M.S. from the University of Regensburg, Germany, and a Ph.D. in medicinal chemistry and pharmacology from the University of Regensburg, Germany. Ambros is qualified to serve on our board of directors due to his management experience in the biotechnology sector and his service on other boards of directors.
Reinhard Ambros is 65, he's been the Lead Independent Director of Aileron Therapeutics Inc since 2018. There are 1 older and 11 younger executives at Aileron Therapeutics Inc. The oldest executive at Aileron Therapeutics Inc is Nolan Sigal, 70, who is the Independent Director.
Reinhard's mailing address filed with the SEC is 281 Albany St, Cambridge, MA 02139, USA.
Over the last 14 years, insiders at Aileron Therapeutics Inc have traded over $6,473,296 worth of Aileron Therapeutics Inc stock and bought 16,658,005 units worth $51,661,886 . The most active insiders traders include Muneer A Satter, Bioventures Ltd Novartis Ag..., and Armen Shanafelt. On average, Aileron Therapeutics Inc executives and independent directors trade stock every 77 days with the average trade being worth of $908,853. The most recent stock trade was executed by Of Texas/Texas Am Investmen... on 14 June 2024, trading 6,607 units of ALRN stock currently worth $21,539.
aileron is the clinical-stage leader in the field of stapled peptide therapeutics for cancers and other diseases. our lead product candidate, alrn-6924, which is being evaluated in multiple clinical trials, reactivates p53-mediated tumor suppression by targeting both of the primary p53 suppressor proteins mdmx and mdm2. the p53 protein, often referred to as the “guardian of the genome,” is known for its central role in preventing cancer initiation and progression, and its inactivation is essential for the formation of virtually all cancers. we believe that alrn-6924 is the first and only product candidate in clinical development that can inhibit both mdmx and mdm2, which we believe, based on published data and our preliminary clinical results, are equally important in restoring p53 function as the body’s first line of defense against cancer. based on preclinical data and preliminary evidence of safety and anti-tumor activity in our ongoing clinical trials, we believe there may be a sig
Aileron Therapeutics Inc executives and other stock owners filed with the SEC include: